✦ LIBER ✦

Comparative risk of adverse treatment effects in parkinson's disease: Evidence from a large employer population

✍ Scribed by Davis, K.L.; Fitzgerald, T.P.; Kulkarni, A.; Meyers, J.; Svarvar, P.; Hewitt, D.J.

Book ID: 122306180
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 71 KB
Volume: 16
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2013.03.470

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence of adverse treatment effects i

Incidence of adverse treatment effects in parkinson's disease: Evidence from a large employer population

✍ Davis, K.L.; Fitzgerald, T.P.; Meyers, J.; Kulkarni, A.; Svarvar, P.; Hewitt, D. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Economic burden of adverse treatment eff

Economic burden of adverse treatment effects in parkinson's disease: Evidence from a large employer population

✍ Davis, K.L.; Fitzgerald, T.P.; Meyers, J.; Kulkarni, A.; Svarvar, P.; Hewitt, D. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Rimantadine in Parkinson's disease patie

Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series

✍ Carlos Singer; Spiridon Papapetropoulos; Manuel A. Gonzalez; Eugene L. Roberts; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

## Abstract We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α‐methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mea

Demographic and clinical characteristics

Demographic and clinical characteristics, and treatment of cardiovascular risk factors in working age patients with high-risk vascular disease: Findings from a multi-employer U.S. claims database

✍ Zhao, Z.; Zhu, Y.; Fang, Y.; McCollam, P.L. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Behavioral activity and stereotypy in ra

Behavioral activity and stereotypy in rats induced by l-DOPA metabolites: a possible role in the adverse effects of chronic l-DOPA treatment of Parkinson’s disease

✍ Taizo Nakazato; Akitane Akiyama 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 231 KB

Long-term effectiveness of dopamine agon

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

✍ PD MED Collaborative Group, 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 593 KB